Healio

Fitusiran prophylaxis superior to on-demand treatment for severe hemophilia

Please provide your email address to receive an email when new articles are posted on . Once-monthly fitusiran prophylaxis improved outcomes compared with on-demand treatment for patients with severe ...
The American Journal of Managed Care

Prophylactic Treatment Challenges and Considerations for Hemophilia A

This is a video synopsis/summary of an Insights involving Allison Wheeler, MD. Wheeler addresses the nuanced considerations for implementing prophylaxis in patients with mild to moderate hemophilia A, ...
Healio

Concizumab prophylaxis reduces bleeds in hemophilia population ‘with complex treatment needs’

Please provide your email address to receive an email when new articles are posted on . Patients who received prophylactic concizumab had a mean overall annualized bleeding rate of zero compared with ...
Yahoo Finance

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated in adults and ...
Nature

Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation

GVHD is the main procedure-related complication in allogeneic haematopoietic SCT, and the successful prevention and management of this complication is crucial for an optimal outcome. GVHD can be quite ...
Medscape

Prophylaxis Against PJP in ANCA-Associated Vasculitis Also Cuts Risk for Other Serious Infections

Prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) significantly reduced the risk for serious infections by approximately 50% in patients with antineutrophil cytoplasmic antibody ...
Yahoo Finance

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH ...

New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated with no safety ...